Nehodí sa? Žiadny problém! U nás môžete do 30 dní vrátiť
S darčekovým poukazom nešliapnete vedľa. Obdarovaný si za darčekový poukaz môže vybrať čokoľvek z našej ponuky.
30 dní na vrátenie tovaru
The rise in hepatocellular carcinoma (HCC) mortality rates has caused researchers to focus increased attention on liver cirrhosis, a pathological condition known to lead to HCC. If hepatic fibrosis can be controlled, it follows that the risk of HCC among patients with chronic hepatitis can be reduced. In the quest for greater understanding of liver cirrhosis, the 1999 Yamaguchi Symposium on Liver Diseases brought together leading researchers in the field. Guest speakers included Michael J.P. Arthur, on mechanisms of the progression and regression of liver fibrosis; Mark A. Zern, on novel therapeutic modalities for hepatic disease; and Jiro Fujimoto, on gene therapy to inhibit progression to liver cirrhosis. The presentations by these groundbreaking scientists are collected in this volume along with those of other leading researchers in the field of hepatology, creating a valuable source for professionals concerned with hepatic fibrogenesis and hepatocarcinogenesis.